Hearing Disorders – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Hearing Disorders – Drugs In Development, 2023’, provides an overview of the Hearing Disorders pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hearing Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hearing Disorders and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hearing Disorders
- The report reviews pipeline therapeutics for Hearing Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hearing Disorders therapeutics and enlists all their major and minor projects
- The report assesses Hearing Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hearing Disorders
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hearing Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
13therapeutics IncAcousia Therapeutics GmbH
Adare Pharma Solutions
Affichem SA
Akouos Inc
Anida Pharma Inc
Antion Biosciences SA
Arbormed Co Ltd
AudioCure Pharma GmbH
Audion Therapeutics BV
Autifony Therapeutics Ltd
Bodor Laboratories Inc
Boehringer Ingelheim International GmbH
Calliditas Therapeutics France SAS
Chaperone Therapeutics Inc
CILcare SAS
Daewoong Pharmaceutical Co Ltd
Dendrogenix SA
Gateway Biotechnology Inc
Hoba Therapeutics ApS
HuidaGene Therapeutics Co Ltd
IMD Farm Co Ltd
ImmunityBio Inc
iN Therapeutics Inc
Jacaranda Biosciences Inc
Knopp Biosciences LLC
Kyungpook National University
Lineage Cell Therapeutics Inc
Massachusetts Institute of Technology
Mogrify Ltd
Myrtelle Inc
NeurAegis Inc
Nobelpharma Co Ltd
Novartis AG
O-Ray Pharma Inc
Oblato Inc
Otologic Pharmaceutics Inc
Otonomy Inc
Paean Biotechnology Inc
Pasteur Institute
Perceive Biotherapeutics Inc
Prime Medicine Inc
Quark Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
ReNeuron Group Plc
Rescue Hearing Inc
Rinri Therapeutics Ltd
Rophibio Inc
Sensorion SA
Sinfonia Biotherapeutics Inc
SIU School of Medicine
Sound Pharmaceuticals Inc
Spiral Therapeutics Inc
St. Jude Children’s Research Hospital Inc
Surrozen Inc
Swedish Orphan Biovitrum AB
Ting Therapeutics LLC
Yonsei University
Zebra Biologics Inc